
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Investment analysts at HC Wainwright decreased their Q4 2027 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of $0.14 per share for the quarter, down from their previous forecast of $0.19. HC Wainwright currently has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.48) per share.
Several other brokerages also recently commented on IONS. The Goldman Sachs Group cut their price objective on Ionis Pharmaceuticals from $58.00 to $41.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 10th. Wells Fargo & Company reduced their target price on Ionis Pharmaceuticals from $95.00 to $80.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 10th. Canaccord Genuity Group decreased their target price on Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, September 8th. Oppenheimer lowered their target price on shares of Ionis Pharmaceuticals from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Tuesday, November 10th. Finally, Royal Bank Of Canada lowered their target price on shares of Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating for the company in a research note on Tuesday, November 10th. Nineteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.
Ionis Pharmaceuticals Price Performance
Shares of IONS stock opened at $26.58 on Thursday. The stock has a 50 day moving average price of $40.76 and a 200 day moving average price of $63.17. Ionis Pharmaceuticals has a 52-week low of $26.53 and a 52-week high of $86.74. The company has a debt-to-equity ratio of 3.42, a quick ratio of 5.36 and a current ratio of 5.43. The firm has a market capitalization of $4.43 billion, a P/E ratio of -8.01 and a beta of 0.43.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The firm had revenue of $242.72 million for the quarter, compared to analysts’ expectations of $178.17 million. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. The company’s quarterly revenue was up 54.8% on a year-over-year basis.
Insider Buying and Selling at Ionis Pharmaceuticals
In other news, Director Michael Hayden bought 5,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was acquired at an average cost of $29.64 per share, with a total value of $148,200.00. Following the transaction, the director directly owned 27,000 shares in the company, valued at approximately $800,280. This trade represents a 22.73% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Shannon Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction on Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the sale, the executive vice president directly owned 17,811 shares of the company’s stock, valued at approximately $775,490.94. This trade represents a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 1.81% of the company’s stock.
Institutional Trading of Ionis Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the company. Laurel Wealth Advisors LLC bought a new position in Ionis Pharmaceuticals during the 3rd quarter worth about $27,000. Cassaday & Co Wealth Management LLC purchased a new position in Ionis Pharmaceuticals during the 1st quarter valued at about $30,000. Root Financial Partners LLC purchased a new position in Ionis Pharmaceuticals during the 3rd quarter valued at about $30,000. Fortitude Family Office LLC raised its holdings in shares of Ionis Pharmaceuticals by 4,411.8% in the 3rd quarter. Fortitude Family Office LLC now owns 767 shares of the company’s stock valued at $34,000 after purchasing an additional 750 shares in the last quarter. Finally, Allworth Financial LP bought a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter valued at about $41,000. 93.86% of the stock is currently owned by institutional investors.
Key Stories Impacting Ionis Pharmaceuticals
Here are a few of the latest stories about IONS:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $70 price target, despite lowering its earnings forecasts. Ionis analyst estimates
- Negative Sentiment: HC Wainwright lowered its earnings estimates across several periods. Its FY2027 loss estimate widened to $1.94 per share from $1.25, and it also cut estimates for Q4 2026 and Q1–Q3 2027. The downward revisions could reinforce concerns about Ionis’s path to profitability. Ionis analyst estimates
- Negative Sentiment: Guggenheim also cut its price target for Ionis, adding to the bearish analyst news; the report provided here does not specify the new target. Ionis Pharmaceuticals stock price target cut by Guggenheim
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Featured Articles
- Five stocks we like better than Ionis Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
